छोड़कर सामग्री पर जाएँ

Latest News

Torrent Pharmaceutical gains on USFDA relief for Dahej plant

Torrent Pharmaceutical gains on USFDA relief for Dahej plant

The FDA#39;s #39;voluntary action indicated classification#39; means that Torrent Pharma will be now able to get approval for all pending Abbreviated New Drug Applications from the site Read More ​ The FDA#39;s #39;voluntary action indicated classification#39; means that Torrent Pharma will… और पढ़ें »Torrent Pharmaceutical gains on USFDA relief for Dahej plant

Daily Voice | Anil Rego of Right Horizons explains why midcaps, smallcaps are being favoured by investors

Daily Voice | Anil Rego of Right Horizons explains why midcaps, smallcaps are being favoured by investors

Anil Rego of Right Horizons sees relative undervaluation in small-caps and select demand pockets that continue to be healthy as the multi-decadal growth outlook structure remains intact. Read More ​ Anil Rego of Right Horizons sees relative undervaluation in small-caps and… और पढ़ें »Daily Voice | Anil Rego of Right Horizons explains why midcaps, smallcaps are being favoured by investors

Daily Voice | Anil Rego of Right Horizons explains why midcaps, smallcaps are being favoured by investors

Daily Voice | Anil Rego of Right Horizons explains why midcaps, smallcaps are being favoured by investors

Anil Rego of Right Horizons sees relative undervaluation in small-caps and select demand pockets that continue to be healthy as the multi-decadal growth outlook structure remains intact. Read More ​ Anil Rego of Right Horizons sees relative undervaluation in small-caps and… और पढ़ें »Daily Voice | Anil Rego of Right Horizons explains why midcaps, smallcaps are being favoured by investors

Navigating Deuruxolitinib#39;s road: HSBC and Nomura weigh in on Sun Pharma#39;s outlook

Navigating Deuruxolitinib#39;s road: HSBC and Nomura weigh in on Sun Pharma#39;s outlook

HSBC and Nomura maintain buy ratings, with HSBC increasing target price to Rs 1275 ( 13.5% from earlier) and Nomura to Rs 1313 (from Rs 1138). Read More ​ HSBC and Nomura maintain buy ratings, with HSBC increasing target price to… और पढ़ें »Navigating Deuruxolitinib#39;s road: HSBC and Nomura weigh in on Sun Pharma#39;s outlook

Concorde Group eyes Rs 900 crore revenue from new Bengaluru launches within 2 years

Concorde Group eyes Rs 900 crore revenue from new Bengaluru launches within 2 years

There aren’t enough homes to meet demand for luxury housing in Bengaluru after the pandemic. Read More ​ There aren’t enough homes to meet demand for luxury housing in Bengaluru after the pandemic. There aren’t enough homes to meet demand for… और पढ़ें »Concorde Group eyes Rs 900 crore revenue from new Bengaluru launches within 2 years

hi_INहिन्दी